January 21, 2014 12:09 PM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Needham's Chad Messer raised Sarepta (NASDAQ: SRPT) from Hold to Buy Tuesday morning, also setting a new $36 price target on the stock.Messer sees Sarepta's Duchenne muscular dystrophy treatment dirsapersen as being ultimately approved, but warned a Phase 3 study may be needed before the company can file a new drug application with the FDA.Earlier this month, Prosensa (NASDAQ: RNA) stated that data supports earlier and longer treatment with DMD drugs which, upon approval of dirsapersen, could provide future gains for Sarepta shares. The stock surged 40 percent on that trading session; Prosensa shares surged almost 25 percent on the same day.Sarepta shares are currently trading at $28.05, up approximately 5 percent for the day. Messer's new price target implies potential upside of about 28 percent.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.